Drug Discontinuation and Follow-up Rates in Oral Antithrombotic Trials

JAMA Internal Medicine

Researcher examined participant loss–to–follow-up rates for major trials of oral antithrombotics, comparing rates reported in medical journals with rates using data submitted by manufacturers to FDA and found published rates were consistently lower than FDA rates (0.4% vs. 12%).

Elocta [rFVIIIFc] launched in UK for prophylaxis and on-demand treatment of bleeding in patients with haemophilia A

PharmaTimes

Elocta [rFVIIIFc], a fully recombinant fusion protein, is first haemophilia A treatment approved in Europe that offers prolonged protection against bleeding episodes through prophylactic injections every 3-5 days instead of every other day with conventional therapies.

Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral Anticoagulants for Atrial Fibrillation

American Journal of Cardiology

Analysis of 4 RCTs of NOACs for treatment of nonvalvular AF (n=58,338) noted that their use was linked to reduced risk of stroke or systemic embolism, and reduced risk of major bleeding compared with warfarin in subjects with mild or moderate renal impairment.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services